BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharma Journalist - ECPv6.16.2//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Pharma Journalist
X-ORIGINAL-URL:https://www.pharmajournalist.com
X-WR-CALDESC:Events for Pharma Journalist
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Asia/Kolkata
BEGIN:STANDARD
TZOFFSETFROM:+0530
TZOFFSETTO:+0530
TZNAME:IST
DTSTART:20200101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210921
DTEND;VALUE=DATE:20210924
DTSTAMP:20260515T212834
CREATED:20210524T075240Z
LAST-MODIFIED:20210625T075240Z
UID:30287-1632182400-1632441599@www.pharmajournalist.com
SUMMARY:3rd Annual RAS–Targeted Drug Development Summit
DESCRIPTION:As 2021 marks a major milestone for RAS therapeutics\, with the first ever KRAS targeted therapy receiving FDA approval\, the once undruggable RAS family of proteins is no longer impossible to crack. With this significant industry shift\, this community will no doubt continue going from strength to strength and the future looks bright for future development of RAS targeted therapies that safely\, effectively\, and selectively drug all RAS driven cancers beyond those caused by G12C mutation. \n \nThe 3rd Annual RAS Targeted Drug Development Summit is returning once again this September to reunite the biggest community of thought leaders and experts in Oncology\, Cancer Therapeutics and Clinical Development to discuss robust monotherapies or combination strategies capable of specifically targeting different RAS-mutant cancer cells with less toxicity to enhance the impact of RAS therapies against all RAS driven cancers beyond lung. \nVia the latest preclinical\, translational and clinical development data-driven case studies from academic and industry pioneers\, the 3rd RAS Targeted Drug Development Summit is your only comprehensive roadmap to addressing unique challenges and future directions of finally drugging all RAS mutations and associated targets with novel modalities and next generation combination therapies. \nIncorporating tracks taking a deep dive into accelerating emerging modalities\, validating robust combination strategies and advancing clinical development\, this is your opportunity to gain extensive strategic and scientific information enabling you to solve the exact challenges you’re encountering to support development of safe and effective next generation RAS targeted therapies. \nTo know more about 3rd Annual RAS–Targeted Drug Development Summit please click here.
URL:https://www.pharmajournalist.com/event/3rd-annual-ras-targeted-drug-development-summit/
LOCATION:Digital Event\, EDT
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210921
DTEND;VALUE=DATE:20210924
DTSTAMP:20260515T212834
CREATED:20210524T114355Z
LAST-MODIFIED:20210524T114355Z
UID:30320-1632182400-1632441599@www.pharmajournalist.com
SUMMARY:4th International Cannabinoid Derived Pharmaceuticals Summit
DESCRIPTION:The Cannabinoid Derived Pharmaceuticals Summit is the world’s largest conference devoted exclusively to the production of CDPs for medical conditions using FDA/EMA approval pathways. The 2021 agenda will focus on clinical trial design and commercialization\, target biology and pharmacology\, GMP-compliant product formulation\, drug delivery\, and managing the changing regulatory environment (particularly in light of new policies from the US government administration). \n \nThe Three-day Program Spans: \n\nA brand-new section dedicated to building a robust clinical strategy will equip you with the knowledge that gave world leading cannabinoid drug developers a commercial and clinical edge in the race to approval\nAnalyzing new discoveries in cannabinoid pharmacology and ECS biology to identify new opportunities\nDiscussion of vital IP and investment topics for a comprehensive update on the health of the industry\nPreparation for post-approval through exploration of key issues relating to commercialization and supply chain management of cannabinoid medicine products and APIs\n\nThe 4th International Cannabinoid-Derived Pharmaceuticals Summit brings together drug developers working on the complex and difficult production of both plant-based and synthetic endocannabinoid system modulators. An elite panel of speakers will discuss important topics such as rigorous clinical trial data exchange\, guided discussion\, and industry networking. \nMeet face-to-face with decision makers from the likes of Greenwich Biosciences\, ACHEM\, Cannvalate\, Cannabics Pharmaceuticals\, Oxford Cannabinoid Technologies and more at the first physical cannabinoid conference of the year. \nTo know more about 4th International Cannabinoid Derived Pharmaceuticals Summit please click here.
URL:https://www.pharmajournalist.com/event/4th-international-cannabinoid-derived-pharmaceuticals-summit/
LOCATION:Aloft Boston Seaport District\, 401-403 D St\, Boston\, MA\, 02210\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210921
DTEND;VALUE=DATE:20210924
DTSTAMP:20260515T212834
CREATED:20210525T115351Z
LAST-MODIFIED:20210525T115440Z
UID:30335-1632182400-1632441599@www.pharmajournalist.com
SUMMARY:2nd Gene Therapy for Ophthalmic Disorders
DESCRIPTION:Returning in September as a digital event\, the 2nd Gene Therapy for Ophthalmic Disorders meeting will target the industry’s translational challenges in targeting both rare and common ophthalmic disorders including wet AMD\, dry AMD\, DME\, IRDs and more. \nDiscover novel vectors and administration routes for optimal retinal delivery with 30+ world class speakers from the likes of GenSight Biologics\, Biogen\, Gyroscope Therapeutics\, Novartis\, Horama and REGENXBIO \n \nJoin 150+ fellow industry attendees from discovery\, preclinical and clinical backgrounds\, to learn lessons in rare disorders and seize the opportunity in common ophthalmic disorders. \nThis meeting will allow you to: \n\nHear the latest data in ocular gene therapy immunogenicity and vector strategies to overcome Inflammation\nHighlight optogenetics and gene agnostic approaches from SparingVision\, GenSight Biologics and Bionic Sight\nLearn how Clearside Biomedical are progressing suprachoroidal delivery with the potential to minimize invasive surgical procedures\nDiscuss the clinical progress with different administration routes to the eye with clinical experience from REGENXBIO\nGain key vector insights from Eyevensys\, who are developing non-viral vectors to minimize immune response and increase likelihood or re-dosing\nExplore the realities of clinical trial design to meet regulatory expectations throughout a program\, with insights from Gensight Biologics\nHear pharma representatives discuss the opportunities and realities of collaborating with biotechs\, with experience from Novartis\nHear from a Luxturna patient to understand their first-hand experience of receiving the therapy\, and have an opportunity to ask them your questions\nHighlighting progress in ASOs for ophthalmic disorders for a deeper understanding of the ophthalmic landscape with data from ProQR\n\nView the event guide here for full agenda details and the expert speaker faculty.
URL:https://www.pharmajournalist.com/event/2nd-gene-therapy-for-ophthalmic-disorders/
LOCATION:Digital Event
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210921
DTEND;VALUE=DATE:20210924
DTSTAMP:20260515T212834
CREATED:20210610T122026Z
LAST-MODIFIED:20210610T122340Z
UID:30508-1632182400-1632441599@www.pharmajournalist.com
SUMMARY:6th Annual PREDiCT: 3D Tissue Models Summit
DESCRIPTION:The 6th PREDiCT: 3D Tissue Models Summit is the only industry-led summit focusing on real-world application of 3D models in drug discovery and development. With 25+ experts sharing fresh case studies on 3D Tissue Models data\, how to foster technology maturation\, and lower costs to drive industrial adoption\, this is a conversation not to miss. \n \nReturning as an in-person meeting in Boston\, our 2021 program will delve further into advanced 3D organoids\, organ-on-chips\, microphysiological systems (MPS)\, and tissue engineering – from oncology to other therapeutic areas – not only in preclinical safety and toxicology models but also back to translation in clinical Ph1 for biomarkers and patient stratification for better Ph2 design. \nJoin 80+ experts on scientific and real-world application dialogues with the likes of FDA\, GSK\, Takeda\, MIT\, and many more\, sharing their journeys and lessons learned with complex in vitro models\, compared with conventional in vivo and 2D cell studies. \nTo find out more and view the 2021 speaker line-up\, download the full event guide. \nBook with confidence! – As the world begins to re-open and in-person events become a reality\, join us again in Boston for the first time in more than a year\, to learn expert insights and generate quality industry connections in a face-to-face capacity. See how we’ll ensure your safety here.
URL:https://www.pharmajournalist.com/event/6th-annual-predict-3d-tissue-models-summit/
LOCATION:The Colonnade Boston – 120 Huntington Avenue\, Boston\, MA 02116\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210922
DTEND;VALUE=DATE:20210924
DTSTAMP:20260515T212834
CREATED:20200416T105628Z
LAST-MODIFIED:20200710T092049Z
UID:25059-1632268800-1632441599@www.pharmajournalist.com
SUMMARY:Oligonucleotide Therapeutics and Delivery Conference
DESCRIPTION:On the way to maximising the potential of oligo-based medicine \nOligonucleotide therapeutics – the emerging medicine class – are harnessing the therapeutic benefit of targeting genetic material via antisense\, mRNA\, RNAi\, saRNA and siRNA. Their market growth: CAGR of 13.7% projected to reach USD 8.2 billion by 2024 is driven by their potential to provide more efficacious and less toxic alternatives to small molecules. They bring about the ability to affect targets that have been considered “non-draggable”. Heavy investments in oligonucleotide therapeutic discovery have created an emerging market need for drug delivery technologies. \n \nSMi’s inaugural Oligonucleotide Therapeutics and Delivery conference is here to keep you updated. By bringing together leading representatives of pharmaceutical\, biotechnology and academic institutions\, the 2-day conference will provide first-hand information on the latest clinical trial candidates and a platform for exchanging ideas for tackling the biggest challenge: DELIVERY. From optimizing particle size to choosing the right nanocarrier systems\, the conference will address delivery to non-hepatocyte cells such as cancerous tissues and overview the most successful platforms. Discussions will be centered around improving targeted therapy uniting the field’s biggest players to share their opinions. \nEstablished on the success of our RNA Therapeutics series\, we look forward to welcoming you at Oligonucleotide Therapeutics and Delivery to join the conversation around maximizing the potential of oligo-based treatments. \nBenefits of attending: \n\nGain first-hand insight into oligonucleotide therapy clinical success up to date for improving development of novel agents in your pipeline\nListen to case studies presenting the latest candidates undergoing pre-clinical and clinical research\nDeepen your understanding of crucial delivery methods and available platforms for non-hepatocytic delivery\nCollaborate with members of the oligonucleotide community leading pharmaceutical\, biotechnology and academic representatives to maximise future opportunities\n\nPlus\, an interactive half day pre-conference workshop on Oligonucleotide drug discovery: Target selection\, delivery\, molecular design and lead identification. \nCHAIR FOR 2021:  \n\nNagy Habib\, Head of HBP Surgery\, Imperial College London and Co-Founder\, Head CNN of R&D and Chief Medical Officer\, Mina Therapeutics\n\nSCIENTIFIC ADVISORY BOARD 2021:\n \n\nEkkehard Leberer\, Senior Director\, Alliance Management\, Sanofi\nMark Edbrooke\, Independent Consultant\nTroels Koch\, Chief Technology Officer\, SVP Science and Technology\, Inexos Therapeutics\nSudhir Agrawal\, Founder and President\, ARNAY Sciences and Idera Pharma and Professor\, University of Massachusetts Medical School\n\nFEATURED 2021 SPEAKERS INCLUDE:  \n\nDavid Evans\, Chief Scientific Officer\, Sirnaomics\nAlexey Wolfson\, CEO\, Advirna\nStefan Vonhoff\, VP Chemistry & Manufacturing\, NOXXON Pharma\nVera Brinks\, Director Pharmaceutics\, ProQR Therapeutics\nMatthew Catley\, Research Director\, MiNa Therapeutics\nSteve Pascolo\, Founder and CEO\, Miescher Pharma\n\nWho should attend: \n\nRNA Biology/Discovery\nNovel Therapeutic Modalities\nInnovation Technologies\nC-level Scientific Executives\nFormulation and Drug Delivery\nClinical Research and Development\nCell Biology\n\nAdditional Contact Info:\nT: +44 (0)20 7827 6088\nE: hsidhu@smi-online.co.uk \nLinkedIn: @SMi Pharma\nTwitter: #SMiOligonucleotides
URL:https://www.pharmajournalist.com/event/oligonucleotide-therapeutics-and-delivery-conference/
LOCATION:Holiday Inn Kensington Forum\, London\, London\, United Kingdom
ORGANIZER;CN="SMi Group":MAILTO:hsidhu@smi-online.co.uk
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210922
DTEND;VALUE=DATE:20210924
DTSTAMP:20260515T212834
CREATED:20200427T082728Z
LAST-MODIFIED:20200605T145115Z
UID:25298-1632268800-1632441599@www.pharmajournalist.com
SUMMARY:Aseptic Processing Conference
DESCRIPTION:SMi’s Aseptic Processing Conference\nExploring aseptic facility design and operation to implement agile contamination control strategies Conference: 22 – 23 September 2021\nLocation: Copthorne Tara Hotel\, London\, UK\nWebsite: http://www.asepticprocessing.co.uk/PJWL \nSPONSORED BY: Innerspace & Steris  \nCHAIRED BY: James Drinkwater\, Head of Aseptic Processing & Containment Special Interest Group\, PHSS and Richard Denk\, DACH Affiliate\, ISPE  \n \nThe aseptic processing industry has seen many changes during its progression towards the 21st century. With advances in innovative therapeutic manufacturing such as ATMPs\, pragmatic barrier system applications\, adaptability and modularity in fill finish\, robotics and automation\, small and agile product manufacturing\, just to name a few. In 2018\, the global aseptic processing market was valued over $56 trillion and is estimated to increase in net revenue upwards $124 trillion by 2027\, with a CAGR growth of 9.18%. \nThe industry is ever changing and with the advent of innovative therapeutics taking hold\, regulators and industry leaders are prompted to take proactive approaches to get treatments to patients faster. \nJoin us to explore novel and developing technologies that tackle the most pressing challenges and push innovation in the world of aseptic processing and sterile manufacturing.  \nEvent Hashtag: #SMiAseptic \nAt the Aseptic Processing Conference\, you will gain insight into: \nFeatured 2021 Speakers include: \n\nScott Nichols\, Microbiologist\, FDA\nSerena Ambrosini\, Sterile Manufacturing Manager\, AstraZeneca\nJim Polarine\, Senior Technical Service Manager\, Steris Corporation\nDi Morris\, Audit Manager CAG\, GSK\nStephen Yang\, Director\, Global Sterile Validation COE\, Merck\nKevin Jenkins\, Consultant\, Quality Excellence Consulting\n\n KEY HIGHLIGHTS INCLUDE FOR 2021 \n\nDiscuss the latest regulatory updates in the industry from leading regulatory bodies\nListen to global case studies in aseptic competence from companies pioneering in the pharmaceutical industry\nExplore advances in ATMP facility design that are revolutionising aseptic manufacturing\nDelve into the newest contamination control technologies from VHP disinfection to fully automated pipelines \n\nPLUS – Pre-conference workshop on… \nContamination control measures in Good Manufacturing Practice (GMP) applied to Aseptic processing \nWorkshop leaders:  James Drinkwater\, Head of Aseptic Processing and Containment Special Interest Group\, PHSS and Kevin Jenkins\, Consultant\, Quality Excellence Consulting \nView the brochure and to download visit http://www.asepticprocessing.co.uk/PJWL
URL:https://www.pharmajournalist.com/event/aseptic-processing-conference/
LOCATION:COPTHORNE TARA HOTEL\, Scarsdale Place\, Kensington\, London\, W8 5SY\, United Kingdom
ORGANIZER;CN="SMi Group":MAILTO:ssapal@smi-online.co.uk
END:VEVENT
END:VCALENDAR